Literature DB >> 7750121

Detection of oligoclonal T lymphocytes in lymph nodes draining from advanced non-small-cell lung cancer.

M Meta1, M Ponte, M Guastella, C Semino, G Pietra, G B Ratto, G Melioli.   

Abstract

Despite the combined use of surgery and chemoradiotherapy, the poor prognosis of advanced non-small-cell lung cancer (NSCLC) requires the definition of new therapeutic approaches. The presence of T lymphocytes, with peculiar phenotypic, functional and molecular characteristics within the tumour, suggested the possible use of these cells, expanded in vitro, in protocols of adoptive immunotherapy. We have described how a population of oligoclonal T lymphocytes, derived from advanced NSCLC, can be expanded in vitro and has the capability of lysing autologous cancer cells. What is more important, we observed that patients with advanced NSCLC, treated with TIL expanded in vitro and recombinant interleukin-2, seemed to have a disease-free period longer than that of patients treated with conventional chemoradiotherapy. In an attempt to find new sources of specific lymphocytes for immunotherapy, we describe the analysis of the phenotypic, functional and molecular characteristics of T lymphocytes, derived from lymph nodes draining advanced NSCLC. In this paper we show that these cells, have restriction patterns of T cell receptor beta chain similar to those detectable in the population of infiltrating T lymphocytes. This finding suggests that T cells derived from draining lymph nodes of advanced NSCLC have peculiar characteristics and can be a suitable source of effector cells for protocols of adoptive immunotherapy in lung cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7750121     DOI: 10.1007/BF01519897

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  10 in total

Review 1.  A new international staging system for lung cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1986-04       Impact factor: 9.410

Review 2.  Postoperative chemotherapy for non-small-cell lung cancer.

Authors:  E C Holmes
Journal:  Chest       Date:  1993-01       Impact factor: 9.410

3.  Sequence and expression of transcripts of the human T-cell receptor beta-chain genes.

Authors:  Y Yoshikai; D Anatoniou; S P Clark; Y Yanagi; R Sangster; P Van den Elsen; C Terhorst; T W Mak
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

4.  Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity.

Authors:  A Moretta; G Pantaleo; L Moretta; J C Cerottini; M C Mingari
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

5.  T-cell receptor gene rearrangements as markers of lineage and clonality in T-cell neoplasms.

Authors:  F Flug; P G Pelicci; F Bonetti; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

6.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

7.  Oligoclonal T lymphocytes infiltrating human lung cancer tissues.

Authors:  I Yoshino; T Yano; Y Yoshikai; M Murata; K Sugimachi; G Kimura; K Nomoto
Journal:  Int J Cancer       Date:  1991-03-12       Impact factor: 7.396

8.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

9.  Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterisation for their use in adoptive immunotherapy.

Authors:  G Melioli; G Ratto; M Guastella; M Meta; R Biassoni; C Semino; G Casartelli; W Pasquetti; A Catrullo; L Moretta
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

10.  Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study.

Authors:  G B Ratto; G Melioli; P Zino; C Mereu; S Mirabelli; G Fantino; M Ponte; P Minuti; A Verna; P Noceti
Journal:  J Thorac Cardiovasc Surg       Date:  1995-06       Impact factor: 5.209

  10 in total
  1 in total

Review 1.  Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.

Authors:  Martin R Jadus; Josephine Natividad; Anthony Mai; Yi Ouyang; Nils Lambrecht; Sandor Szabo; Lisheng Ge; Neil Hoa; Maria G Dacosta-Iyer
Journal:  Clin Dev Immunol       Date:  2012-07-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.